THE MULTI-KINASE INHIBITOR EC-70124 SYNERGISTICALLY INCREASED THE ANTI-TUMOR ACTIVITY OF DOXORUBICIN IN SARCOMAS.

Related Articles

THE MULTI-KINASE INHIBITOR EC-70124 SYNERGISTICALLY INCREASED THE ANTI-TUMOR ACTIVITY OF DOXORUBICIN IN SARCOMAS.

Int J Cancer. 2018 Dec 21;:

Authors: Estupiñan O, Santos L, Rodriguez A, Fernandez-Nevado L, Costales P, Perez-Escuredo J, Hermosilla MA, Oro P, Rey V, Tornín J, Allonca E, Fernández-García MT, Alvarez-Fernández C, Braña A, Astudillo A, Menendez ST, Morís F, Rodriguez R

Abstract
Cytotoxic drugs like doxorubicin remain as the most utilized agents in sarcoma treatment. However, advanced sarcomas are often resistant, thus stressing the need for new therapies aimed to overcome this resistance. Multi-kinase inhibitors provide an efficient way to target several pro-tumorigenic pathways using a single agent and may constitute a valuable strategy in the treatment of sarcomas, which frequently show an aberrant activation of pro-tumoral kinases. Therefore, we studied the antitumor activity of EC-70124, an indolocarbazole analog that have demonstrated a robust ability to inhibit a wide range of pro-survival kinases. Evaluation of the phospho-kinase profile in cell-of-origin sarcoma models and/or sarcoma primary cell lines evidenced that PI3K/AKT/mTOR, JAK/STAT or SRC were among the most highly activated pathways. In striking contrast with the structurally related drug midostaurin, EC-70124 efficiently prevented the phosphorylation of these targets and robustly inhibited proliferation through a mechanism associated to the induction of DNA damage, cell cycle arrest and apoptosis. In addition, EC-70124 was able to partially reduce tumor growth in vivo. Importantly, this compound inhibited the expression and activity of ABC efflux pumps involved in drug resistance. In line with this ability, we found that the combined treatment of EC-70124 with doxorubicin resulted in a synergistic cytotoxic effect in vitro and an increased anti-tumor activity of this cytotoxic drug in vivo. Altogether, these results uncover the capability of the novel multikinase inhibitor EC-70124 to counteract drug resistance in sarcoma and highlight its therapeutic potential when combined with current treatments. This article is protected by copyright. All rights reserved.

PMID: 30575954 [PubMed - as supplied by publisher]

from A via a.sfakia on Inoreader http://bit.ly/2GBFwvX